<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556475</url>
  </required_header>
  <id_info>
    <org_study_id>D5252R00002</org_study_id>
    <nct_id>NCT03556475</nct_id>
  </id_info>
  <brief_title>Development of AECOPD Identification Tool (DETECT Study)</brief_title>
  <official_title>A Diagnostic Test to Develop an AECOPD Identification Tool Through Characteristic Variables Extracted From Diagnosed AECOPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an observational, multi-center and cross sectional study,to develop an&#xD;
      identification tool on purpose of differentiating COPD exacerbation from patients with&#xD;
      respiratory symptoms in community hospitals of China.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, multi-center and cross-sectional study to develop an AECOPD&#xD;
      identification tool. Estimated totally 7 tertiary hospitals with experts in respiratory area&#xD;
      will be involved as the study sites. These study sites will cover the regions of China&#xD;
      (Eastern, Southern, Northern, Central, Western and Northeastern region), to be representative&#xD;
      for the patient features all over the country. The patients will be enrolled in a&#xD;
      &quot;consecutive&quot; way, which is, the investigators will recruit the patients who are eligible and&#xD;
      consented to participate in this study without personal tendency.&#xD;
&#xD;
      For the enrolled patients, a face to face visit between investigator and patient will be&#xD;
      arranged. The evaluation for the symptoms and signs will be performed and the relevant data&#xD;
      will be collected on the visit. In addition, other relevant tests (e.g. oxygen saturation,&#xD;
      blood test, CAT, etc) and data (demographic, medical history, etc) will be collected on this&#xD;
      visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 28, 2020</start_date>
  <completion_date type="Actual">January 18, 2021</completion_date>
  <primary_completion_date type="Actual">January 18, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity(Sen) &amp; Specificity(Spe)</measure>
    <time_frame>Dec2017--Mar2020</time_frame>
    <description>Each candidate factors will be tested and weighed. 6-8 factors are estimated to be identified and modelled to form AECOPD identification scale. The validity and efficacy of AECOPD identification tools will be assessed by internal verification.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Acute Exacerbations of COPD</condition>
  <arm_group>
    <arm_group_label>Disease 1</arm_group_label>
    <description>Moderate to severe COPD Patients(n=90)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Disease type 2-1)</arm_group_label>
    <description>Patients with Mild/moderate AECOPD (n=60)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Disease type 2-2)</arm_group_label>
    <description>Patients with Severe AECOPD( n=60)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Disease type 3</arm_group_label>
    <description>Non-COPD Patients with high risk factors (n=90)</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      This is an observational study and no samples will be collected.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Disease type 1 : Moderate to severe COPD Patients(n=90); Disease type 2 : Patients with&#xD;
        AECOPD&#xD;
&#xD;
        a) Mild/moderate: n=60 c) Severe: n=60 Disease type 3 : Non-COPD Patients with high risk&#xD;
        factors (n=90)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -≥ 40 years old of age.&#xD;
&#xD;
          -  Able to adequately understand written and verbal&#xD;
&#xD;
          -  A signed and dated written informed consent must be obtained prior to the visits&#xD;
&#xD;
          -  Patients see doctors due to suffering respiratory disease below:&#xD;
&#xD;
        Disease type 1 - diagnosed moderate and severe stable COPD&#xD;
&#xD;
          -  Patients with a diagnosis of COPD and documented record with predicted ratio of FEV1&#xD;
             to forced vital capacity (FVC) &lt; 0.70 before the study visit&#xD;
&#xD;
          -  COPD with moderate to severe airflow obstruction (FEV1&lt;0.8 predicted)&#xD;
&#xD;
        Disease type 2 - AECOPD&#xD;
&#xD;
          -  Patients with a diagnosis of COPD and documented record with predicted ratio of FEV1&#xD;
             to forced vital capacity (FVC) &lt; 0.70 before the study visit&#xD;
&#xD;
          -  Patients consult the clinic or the emergency department because of acute worsening&#xD;
             with an AECOPD (diagnosed by more than 2 clinical experts and refer to diagnosis&#xD;
             criteria of Appendix 2)&#xD;
&#xD;
        Disease type 3&#xD;
&#xD;
        -Non-COPD patients with chronic respiratory symptoms such as cough, sputum and wheeze,&#xD;
        dyspnea etc. (≥2 high risk factors )&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with severe cardiovascular disease, including uncontrolled hypertension with&#xD;
             drug treatment, unstable angina, myocardial infarction within the last 6 months, NYHA&#xD;
             class II congestive heart failure, severe arrhythmia, pericardial effusion, etc.&#xD;
&#xD;
          -  Patients with lung cancer, esophageal cancer or mediastinal tumors;&#xD;
&#xD;
          -  Patients who participated in any drug clinical trials within 4 weeks before&#xD;
             enrollment;&#xD;
&#xD;
          -  Patients with severe infection, indicated for intravenous antibiotics, antifungal or&#xD;
             antiviral therapy;&#xD;
&#xD;
          -  Patients suffering from mental illness and poor compliance;&#xD;
&#xD;
          -  Patients inappropriate for inclusion decided by investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian KANG, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>No 155. Nanjing street, Heping District, Liaoning Province</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenyang</city>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xi'an</city>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xinxiang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 10, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

